[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368657-105":59,"doc-detail-368657-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","ttc36-as-a-prognostic-biomarker-in-nonmetastatic-hepatocellular-carcinoma-a-tcga-based-cohort-study","TTC36 as a prognostic biomarker in nonmetastatic hepatocellular carcinoma - A TCGA-based cohort study","","Nonmetastatic hepatocellular carcinoma (nMHC) is a prevalent primary liver cancer with distinct molecular and clinical features. This TCGA-based study evaluates tetratricopeptide repeat domain 36 (TTC36) as a diagnostic and prognostic biomarker in nMHC. TTC36 expression is lower in tumor and adjacent nontumor tissues versus normal liver. ROC analysis shows strong diagnostic performance (AUC 0.960), while high TTC36 independently predicts better overall survival and improved survival endpoints (P \u003C .05). TTC36-high status suppresses multiple metabolic pathways and shows inverse correlations with immune cell infiltration, suggesting relevance to tumor immune microenvironment modulation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ttc36-as-a-prognostic-biomarker-in-nonmetastatic-hepatocellular-carcinoma-a-tcga-based-cohort-study/368657/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ttc36-as-a-prognostic-biomarker-in-nonmetastatic-hepatocellular-carcinoma-a-tcga-based-cohort-study/368657.png","ImageObject",300,407,{"name":92,"@type":93},"Đào","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How does TTC36 perform as a diagnostic marker for nMHC?","Question",{"text":112,"@type":113},"TTC36 expression is significantly lower in nMHC tissues than in normal liver and adjacent nontumor tissues. Receiver operating characteristic analysis yields an AUC of 0.960 (95% CI: 0.941–0.978).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is the prognostic value of TTC36 in nonmetastatic hepatocellular carcinoma?",{"text":117,"@type":113},"Higher TTC36 expression independently predicts better overall survival (HR = 0.536, P = .001) and is associated with improved disease-specific survival, disease-free interval, and progression-free interval (P \u003C .05).",{"name":119,"@type":110,"acceptedAnswer":120},"How is TTC36 linked to tumor biology and immune infiltration?",{"text":121,"@type":113},"Gene set enrichment analysis indicates that high TTC36 suppresses peroxisome and multiple metabolic pathways including glycolysis/gluconeogenesis and steroid hormone biosynthesis. TTC36 expression shows negative correlations with immune cell infiltration, suggesting an effect on the tumor immune microenvironment.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368657,1791288310,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374402968488,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","®  \n Observational Study   \nTTC36 as a prognostic biomarker in nonmetastatic hepatocellular carcinoma A TCGA-based cohort study  \nLixin Li, BDa , Jingchun Wang, BDa ,*  \n\n| Abstract\u003Cbr>Nonmetastatic hepatocellular carcinoma (nMHC) is a common form of primary liver cancer with distinct molecular and clinical characteristics. Tetratricopeptide repeat domain 36 (TTC36), a gene associated with various cancer types, has been implicated in tumorigenesis, but its role in nMHC is not fully understood. This study investigates the role of TTC36 in nMHC using The Cancer Genome Atlas data. Gene expression data and clinical information for nMHC patients were retrieved from the The Cancer Genome Atlas database. Differential expression of TTC36 in tumor and normal tissues was assessed, and diagnostic accuracy was evaluated using receiver operating characteristic analysis. Kaplan–Meier and Cox regression analyses determined the prognostic value of TTC36 . Differentially expressed genes related to TTC36 were identified and analyzed for functional enrichment via Kyoto Encyclopedia of Genes and Genomes and gene set enrichment analysis. A protein–protein interaction network was constructed, and immune infiltration correlations were examined using the tumor immune estimation resource database. TTC36 expression was significantly lower in nMHC tissues compared to normal liver tissues and adjacent nontumor tissues, with an area under the curve of 0.960 (95% CI: 0.941–0.978) for diagnosis. High TTC36 expression correlated with older age, obesity, early T stages, early histological grade, early clinical stages but was inversely related to alpha-fetoprotein. High TTC36 expression independently predicted better overall survival (HR = 0.536, 95% CI: 0.365–0.787, P = .001) and was associated with improved disease-specific survival, disease-free interval, and progression-free interval (P \u003C .05) . Gene set enrichment analysis indicated that high TTC36 expression suppressed peroxisome, metabolism, glycolysis/gluconeogenesis, steroid hormone biosynthesis, and primary bile acid biosynthesis. Negative correlations were observed between TTC36 expression and immune cell infiltration. TTC36 is a promising prognostic biomarker in nonmetastatic hepatocellular carcinoma. Its expression correlates with improved patient outcomes and reduced immune cell infiltration, suggesting its potential as a therapeutic target for modulating the tumor immune microenvironment. |\n| --- |\n| Abbreviations: AFP = alpha-fetoprotein, DEGs = differentially expressed genes, DFI = disease-free interval , DSS = diseasespecific survival, GSEA = gene set enrichment analysis, HCC = hepatocellular carcinoma, KEGG = Kyoto Encyclopedia of Genes and Genomes, nMHC = nonmetastatic hepatocellular carcinoma, OS = overall survival, PFI = progression-free interval, PPI = protein–protein interaction, ROC = receiver operating characteristic, TCGA = The Cancer Genome Atlas, TTC36 = tetratricopeptide repeat domain 36. |\n| Keywords: immune microenvironment, nonmetastatic hepatocellular carcinoma, prognostic biomarker, TCGA, TTC36 |\n\n1. Introduction  \nHepatocellular carcinoma (HCC) is the most common form of primary liver cancer, with a high incidence and mortality rate worldwide.[1,2] The development of HCC is a complex, multistep process that involves both genetic and environmental factors, and it remains a major challenge for clinical management.[3,4] Nonmetastatic HCC (nMHC), which refers to HCC that has not yet spread beyond the liver, represents a significant subset  \nof the disease.[5] Despite advances in diagnostic and therapeutic strategies, prognosis for nMHC remains poor due to its insidious onset and high recurrence rates.[6,7] The identification of reliable prognostic biomarkers is essential for early detection, predicting clinical outcomes, and developing targeted therapies for nMHC.  \nNumerous studies have explored the molecular mechanisms driving HCC progression, focusing on genetic,[8] epigeneti","cbCaiphEyscHABTI","https://ap.wps.com/l/cbCaiphEyscHABTI","pdf",3131445,11,"English","# Introduction\n## Methods\n## Results\n## Discussion","[{\"question\":\"How does TTC36 perform as a diagnostic marker for nMHC?\",\"answer\":\"TTC36 expression is significantly lower in nMHC tissues than in normal liver and adjacent nontumor tissues. Receiver operating characteristic analysis yields an AUC of 0.960 (95% CI: 0.941–0.978).\"},{\"question\":\"What is the prognostic value of TTC36 in nonmetastatic hepatocellular carcinoma?\",\"answer\":\"Higher TTC36 expression independently predicts better overall survival (HR = 0.536, P = .001) and is associated with improved disease-specific survival, disease-free interval, and progression-free interval (P \\u003c .05).\"},{\"question\":\"How is TTC36 linked to tumor biology and immune infiltration?\",\"answer\":\"Gene set enrichment analysis indicates that high TTC36 suppresses peroxisome and multiple metabolic pathways including glycolysis/gluconeogenesis and steroid hormone biosynthesis. TTC36 expression shows negative correlations with immune cell infiltration, suggesting an effect on the tumor immune microenvironment.\"}]","TTC36 as a prognostic biomarker in nonmetastatic hepatocellular carcinoma - A TCGA-based cohort study | PDF",1790177888,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aacb57c93515937163a8e476021f7ea7.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/af8e872b5bc2ee97d6bda8e3789d0ce5.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aba4bab87679251eb9dda8b30e674125.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bbd419478a6e79a006449d4c24639d4e.webp",980,1306]